Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Antares Pharma, Inc. stock logo
ATRS
Antares Pharma
$5.59
$5.59
$3.11
$5.60
$955.06M1.153.29 million shs6 shs
OraSure Technologies, Inc. stock logo
OSUR
OraSure Technologies
$3.07
-1.0%
$2.84
$2.36
$4.92
$229.64M0.45795,139 shs3.01 million shs
Vapotherm, Inc. stock logo
VAPO
Vapotherm
$2.17
$2.16
$0.70
$3.44
$13.58M-1.11N/A51,531 shs
Intersect ENT, Inc. stock logo
XENT
Intersect ENT
$28.24
$28.24
$15.92
$28.25
$954.91M1.45351,526 shs14,512 shs
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Antares Pharma, Inc. stock logo
ATRS
Antares Pharma
0.00%0.00%0.00%0.00%0.00%
OraSure Technologies, Inc. stock logo
OSUR
OraSure Technologies
0.00%+0.65%+5.08%+3.33%-27.91%
Vapotherm, Inc. stock logo
VAPO
Vapotherm
0.00%0.00%0.00%0.00%+1.88%
Intersect ENT, Inc. stock logo
XENT
Intersect ENT
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Antares Pharma, Inc. stock logo
ATRS
Antares Pharma
1.8772 of 5 stars
0.00.00.03.60.60.83.1
OraSure Technologies, Inc. stock logo
OSUR
OraSure Technologies
2.5263 of 5 stars
1.03.00.04.22.01.70.6
Vapotherm, Inc. stock logo
VAPO
Vapotherm
N/AN/AN/AN/AN/AN/AN/AN/A
Intersect ENT, Inc. stock logo
XENT
Intersect ENT
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Antares Pharma, Inc. stock logo
ATRS
Antares Pharma
0.00
N/AN/AN/A
OraSure Technologies, Inc. stock logo
OSUR
OraSure Technologies
2.00
Hold$3.00-2.28% Downside
Vapotherm, Inc. stock logo
VAPO
Vapotherm
0.00
N/AN/AN/A
Intersect ENT, Inc. stock logo
XENT
Intersect ENT
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest ATRS, XENT, OSUR, and VAPO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/19/2025
OraSure Technologies, Inc. stock logo
OSUR
OraSure Technologies
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingIn-Line ➝ In-Line$3.00 ➝ $3.00
(Data available from 7/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Antares Pharma, Inc. stock logo
ATRS
Antares Pharma
$183.98M5.19$0.13 per share43.89$1.03 per share5.43
OraSure Technologies, Inc. stock logo
OSUR
OraSure Technologies
$185.83M1.24$0.04 per share79.85$5.50 per share0.56
Vapotherm, Inc. stock logo
VAPO
Vapotherm
$68.67M0.20N/AN/A($9.01) per share-0.24
Intersect ENT, Inc. stock logo
XENT
Intersect ENT
$106.75M8.95N/AN/A($2.06) per share-13.71
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Antares Pharma, Inc. stock logo
ATRS
Antares Pharma
$46.29M$0.2423.2925.41N/A21.90%7.43%4.92%N/A
OraSure Technologies, Inc. stock logo
OSUR
OraSure Technologies
-$19.50M-$0.42N/AN/AN/A-19.77%-5.86%-5.20%8/5/2025 (Estimated)
Vapotherm, Inc. stock logo
VAPO
Vapotherm
-$58.19M-$8.51N/AN/A-76.74%N/A-68.08%N/A
Intersect ENT, Inc. stock logo
XENT
Intersect ENT
-$159.63M-$4.79N/AN/AN/A-161.94%-709.52%-48.18%N/A

Latest ATRS, XENT, OSUR, and VAPO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/5/2025Q2 2025
OraSure Technologies, Inc. stock logo
OSUR
OraSure Technologies
-$0.15N/AN/AN/A$30.52 millionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Antares Pharma, Inc. stock logo
ATRS
Antares Pharma
N/AN/AN/AN/AN/A
OraSure Technologies, Inc. stock logo
OSUR
OraSure Technologies
N/AN/AN/AN/AN/A
Vapotherm, Inc. stock logo
VAPO
Vapotherm
N/AN/AN/AN/AN/A
Intersect ENT, Inc. stock logo
XENT
Intersect ENT
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Antares Pharma, Inc. stock logo
ATRS
Antares Pharma
0.10
3.08
2.87
OraSure Technologies, Inc. stock logo
OSUR
OraSure Technologies
N/A
12.34
10.94
Vapotherm, Inc. stock logo
VAPO
Vapotherm
N/A
0.25
0.09
Intersect ENT, Inc. stock logo
XENT
Intersect ENT
6.89
1.88
1.50

Institutional Ownership

CompanyInstitutional Ownership
Antares Pharma, Inc. stock logo
ATRS
Antares Pharma
50.41%
OraSure Technologies, Inc. stock logo
OSUR
OraSure Technologies
93.50%
Vapotherm, Inc. stock logo
VAPO
Vapotherm
43.08%
Intersect ENT, Inc. stock logo
XENT
Intersect ENT
92.47%

Insider Ownership

CompanyInsider Ownership
Antares Pharma, Inc. stock logo
ATRS
Antares Pharma
5.90%
OraSure Technologies, Inc. stock logo
OSUR
OraSure Technologies
3.90%
Vapotherm, Inc. stock logo
VAPO
Vapotherm
15.80%
Intersect ENT, Inc. stock logo
XENT
Intersect ENT
2.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
Antares Pharma, Inc. stock logo
ATRS
Antares Pharma
201170.85 million160.77 millionOptionable
OraSure Technologies, Inc. stock logo
OSUR
OraSure Technologies
84074.80 million71.88 millionOptionable
Vapotherm, Inc. stock logo
VAPO
Vapotherm
2906.26 million5.27 millionNo Data
Intersect ENT, Inc. stock logo
XENT
Intersect ENT
43333.81 million33.10 millionOptionable

Recent News About These Companies

Zee Ent. - Zee Entertainment Enterprises Share Price
Kiatnakin Bank PCL (KKP)
At the Intersection of Law & Policy
XENT Historical Data

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Antares Pharma stock logo

Antares Pharma NASDAQ:ATRS

Antares Pharma, Inc., a specialty pharmaceutical company, focuses primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas. It develops, manufactures, and commercializes novel therapeutic products using its drug delivery systems. The company's injection products include XYOSTED for subcutaneous administration of testosterone replacement therapy in adult males; OTREXUP a subcutaneous methotrexate injection indicated for adults with severe active rheumatoid arthritis, children with active polyarticular juvenile idiopathic arthritis, and adults with severe recalcitrant psoriasis; and NOCDURNA sublingual tablets indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least two times per night to urinate. Its injection products also comprise generic Epinephrine Injection USP products indicated for emergency treatment of severe allergic reactions, including anaphylaxis in adults and certain pediatric patients; Sumatriptan Injection USP indicated for the acute treatment of migraine headaches and cluster headache in adults; and Makena subcutaneous auto-injector drug-device combination product indicated to reduce the risk of preterm birth in women, as well as Teriparatide injection used for the treatment of osteoporosis in postmenopausal women and men at increased risk of fracture, and glucocorticoid induced osteoporosis in men and women. In addition, the company develops disposable pen injectors for diabetes and osteoporosis; QuickShot auto-injectors; TLANDO to treat deficiency or absence of endogenous testosterone in adult males; and drug/device products for urologic oncology, immunology, and endocrinology. The company has strategic alliances and partnerships with Pfizer Inc., Idorsia Pharmaceuticals Ltd, Teva Pharmaceutical Industries, Ltd, and AMAG. Antares Pharma, Inc. was incorporated in 1979 and is headquartered in Ewing, New Jersey.

OraSure Technologies stock logo

OraSure Technologies NASDAQ:OSUR

$3.07 -0.03 (-0.97%)
Closing price 04:00 PM Eastern
Extended Trading
$3.08 +0.01 (+0.16%)
As of 07:26 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

OraSure Technologies, Inc., together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company's products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test. It also offers genomic products under the Oragene and ORAcollect brands for collecting genetic material from human saliva; Colli-Pee collection devices for the volumetric collection of void urine samples; and microbiome laboratory testing and analytical services. In addition, the company provides microbiome products, such as OMNIgene GUT for self-collecting microbial DNA from feces or stool samples for gut microbiome profiling; OMNIgene GUT DNA and RNA collection devices; and OMNIgene GUT Dx collection device for collection of human fecal samples and the stabilization of DNA from the bacterial community. Additionally, it provides other diagnostic products, such as immunoassays and other in vitro diagnostic tests. The company markets its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, commercial and industrial entities, disease risk management, diagnostics, pharmaceutical, biotech, nutrition, companion animal, and environmental markets. OraSure Technologies, Inc. was incorporated in 2000 and is based in Bethlehem, Pennsylvania.

Vapotherm stock logo

Vapotherm NYSE:VAPO

Vapotherm, Inc., a medical technology company, focuses on the development and commercialization of proprietary high velocity therapy products used to treat patients of various ages suffering from respiratory distress in the United States and internationally. The company offers High Velocity Therapy systems, such as HVT 2.0, Precision Flow Hi-VNI, Precision Flow Plus, and Precision Flow Classic which delivers non-invasive ventilatory support to patients by providing heated, humidified, and oxygenated air at a high velocity to treat patients through a small-bore nasal interface. It also provides companion products, including Vapotherm Transfer Unit, which allows patients to be transferred between care areas within the hospital or ambulate while on therapy; Q50 compressor that provides compressed air necessary to run the precision flow systems in areas of the hospital without access to a wall gas source; aerosol aeroneb adaptor to facilitate delivery of aerosolized solutions; aerosol disposable patient circuit that is designed to streamline the provision of continuous and intermittent delivery of aerosol solutions for patients; and tracheostomy adaptors that simplifies the connection of the High Velocity Therapy systems to a tracheostomy collar used to wean patients off mechanical ventilation. In addition, the company offers ProSoft cannula to provide gentle contact with the skin; and disposable products comprising single-use disposables and nasal interfaces, as well as Oxygen Assist Module, which helps clinicians maintain oxygen levels within a target range. Vapotherm, Inc. was founded in 1993 and is headquartered in Exeter, New Hampshire.

Intersect ENT stock logo

Intersect ENT NASDAQ:XENT

Intersect ENT, Inc. operates as an ear, nose, and throat (ENT) medical technology company in the United States. The company offers PROPEL, a steroid releasing implant to open the surgically enlarged sinus; PROPEL Mini, a releasing implant to treat patients undergoing frontal sinus surgery; and PROPEL Contour, a steroid releasing implant for the treatment of frontal and maxillary sinus ostia, or openings, of the dependent sinuses. It also provides SINUVA, a steroid releasing implant for the treatment of patients in the physician office setting; VENSURE Navigable and Stand-alone balloon, a sterile and single-use device, used to access and treat frontal, sphenoid sinus, and maxillary ostia in adults using a trans-nasal approach; and CUBE Navigation System, a virtual guidance platform for high precision ENT and ENT related skull-base surgeries. The company was formerly known as Sinexus, Inc. and changed its name to Intersect ENT, Inc. in November 2009. Intersect ENT, Inc. was incorporated in 2003 and is headquartered in Menlo Park, California.